BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1607 related articles for article (PubMed ID: 16572427)

  • 41. Laboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virus.
    Fan H; Nicholls J; Chua D; Chan KH; Sham J; Lee S; Gulley ML
    Int J Cancer; 2004 Dec; 112(6):1036-41. PubMed ID: 15386346
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma.
    Shao JY; Zhang Y; Li YH; Gao HY; Feng HX; Wu QL; Cui NJ; Cheng G; Hu B; Hu LF; Ernberg I; Zeng YX
    Anticancer Res; 2004; 24(6):4059-66. PubMed ID: 15736452
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Application of logistic regression in combination with multiple diagnostic tests for auxiliary diagnosis of nasopharyngeal carcinoma.
    Jiang SQ; Liu Q
    Ai Zheng; 2009 Feb; 28(2):177-80. PubMed ID: 19550133
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
    Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ
    Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Quantitative and localized detection of Epstein-Barr virus infectious status in nasopharyngeal carcinoma tissue].
    Jiang WH; Zhao SP; Yin ZH; Li F; Chen ZH; Xiao JY
    Ai Zheng; 2005 Jul; 24(7):796-800. PubMed ID: 16004803
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr Virus episomal latency.
    Dheekollu J; Malecka K; Wiedmer A; Delecluse HJ; Chiang AK; Altieri DC; Messick TE; Lieberman PM
    Oncotarget; 2017 Jan; 8(5):7248-7264. PubMed ID: 28077791
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area.
    Kalpoe JS; Dekker PB; van Krieken JH; Baatenburg de Jong RJ; Kroes AC
    J Clin Pathol; 2006 May; 59(5):537-41. PubMed ID: 16489178
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epstein-Barr virus gene polymorphism in different parts of the same nasopharyngeal carcinoma patient.
    Nie Y; Sun Y; Wang Y; Liu C; Zhao C; Luo B
    Arch Virol; 2013 May; 158(5):1031-7. PubMed ID: 23266831
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Polymyositis/dermatomyositis and nasopharyngeal carcinoma: the Epstein-Barr virus connection?
    Chen DY; Chen YM; Lan JL; Chen HH; Hsieh CW; Wey SJ; Lu JJ
    J Clin Virol; 2010 Dec; 49(4):290-5. PubMed ID: 20934910
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts.
    Brooks L; Yao QY; Rickinson AB; Young LS
    J Virol; 1992 May; 66(5):2689-97. PubMed ID: 1313894
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A comparison of EBV serology and serum cell-free DNA as screening tools for nasopharyngeal cancer: Results of the Singapore NPC screening cohort.
    Tay JK; Siow CH; Goh HL; Lim CM; Hsu PP; Chan SH; Loh KS
    Int J Cancer; 2020 May; 146(10):2923-2931. PubMed ID: 31705522
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma.
    Chang KP; Hsu CL; Chang YL; Tsang NM; Chen CK; Lee TJ; Tsao KC; Huang CG; Chang YS; Yu JS; Hao SP
    Oral Oncol; 2008 Aug; 44(8):784-92. PubMed ID: 18206420
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A novel and non-invasive approach utilising nasal washings for the detection of nasopharyngeal carcinoma.
    Tan GW; Sivanesan VM; Abdul Rahman FI; Hassan F; Hasbullah HH; Ng CC; Khoo AS; Tan LP
    Int J Cancer; 2019 Oct; 145(8):2260-2266. PubMed ID: 30698824
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical significance of plasma Epstein-Barr Virus DNA loads in a large cohort of Malaysian patients with nasopharyngeal carcinoma.
    Chai SJ; Pua KC; Saleh A; Yap YY; Lim PV; Subramaniam SK; Lum CL; Krishnan G; Mahiyuddin WR; ; Teo SH; Khoo AS; Yap LF
    J Clin Virol; 2012 Sep; 55(1):34-9. PubMed ID: 22739102
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Unique variations of Epstein-Barr virus-encoded BARF1 gene in nasopharyngeal carcinoma biopsies.
    Wang Y; Wang XF; Sun ZF; Luo B
    Virus Res; 2012 Jun; 166(1-2):23-30. PubMed ID: 22406129
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Utility of Epstein-Barr Virus DNA in Nasopharynx Swabs as a Reflex Test to Triage Seropositive Individuals in Nasopharyngeal Carcinoma Screening Programs.
    Chen GH; Liu Z; Yu KJ; Coghill AE; Chen XX; Xie SH; Lin DF; Huang QH; Lu YQ; Ling W; Lin CY; Lu ZJ; Fan YY; Tang LQ; Sampson JN; Li H; King AD; Middeldorp JM; Hildesheim A; Cao SM
    Clin Chem; 2022 Jul; 68(7):953-962. PubMed ID: 35325087
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epstein-Barr virus infection in precursor lesions of nasopharyngeal carcinoma.
    Zhong BL; Zong YS; Lin SX; Zhang M; Liang YJ
    Ai Zheng; 2006 Feb; 25(2):136-42. PubMed ID: 16480574
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Screening nasopharyngeal carcinoma by detection of the latent membrane protein 1 (LMP-1) gene with nasopharyngeal swabs.
    Hao SP; Tsang NM; Chang KP
    Cancer; 2003 Apr; 97(8):1909-13. PubMed ID: 12673717
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Presence of Epstein-Barr virus latent membrane protein 1 gene in the nasopharyngeal swabs from patients with nasopharyngeal carcinoma.
    Lin SY; Tsang NM; Kao SC; Hsieh YL; Chen YP; Tsai CS; Kuo TT; Hao SP; Chen IH; Hong JH
    Head Neck; 2001 Mar; 23(3):194-200. PubMed ID: 11428449
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area.
    Alfieri S; Iacovelli NA; Marceglia S; Lasorsa I; Resteghini C; Taverna F; Mazzocchi A; Orlandi E; Guzzo M; Bianchi R; Fanti D; Pala L; Racca S; Dvir R; Quattrone P; Gloghini A; Volpi CC; Granata R; Bergamini C; Locati L; Licitra L; Bossi P
    Oncotarget; 2017 Jul; 8(29):47780-47789. PubMed ID: 28562354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 81.